Figure 2From: Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II studyKaplan-Meier overall survival (OS) of patients treated with FOLFOX/Bevacizumab.Back to article page